HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 -- HUTCHMED Limited today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new...

Related Keywords

Beijing ,China ,Spain ,Tianjin ,Shanghai ,Oslo ,Norway ,Wuhan ,Hubei ,Ying Qian ,Jiangxi ,Valencia ,Carabobo ,Venezuela ,Cheng Mei ,Guangdong ,Peking ,Hong Kong ,Tongji ,Sichuan ,Texas ,United States ,Houston ,Madrid ,Huazhong ,Chinese ,Renchi Yang ,Pau Montesinos ,Zhou Yi ,Atholl Tweedie ,Mingci Cai ,Hall Mallo ,Xiaojun Huang ,Fengkui Zhang ,Xiaofan Liu ,Ben Atwell Alex Shaw ,Waleed Ghanima ,Tongji Medical College ,Shanghai Jiao Tong University School Of Medicine ,European Hematology Association ,Linkedin ,Nasdaq ,Chinese Academy Of Medical Sciences ,China Limited ,University People Hospital ,Union Hospital ,Huazhong University Of Science ,Institute Of Hematology ,University Of Oslo ,Stock Exchange Of Hong Kong ,Exchange Commission ,University Of Texas Md Anderson Cancer Center ,Hybrid Congress ,Immune Thrombocytopenia ,Syk Inhibitor Sovleplenib ,Adult Patients ,Primary Immune Thrombocytopenia ,Placebo Controlled Phase ,Blood Diseases Hospital ,Chinese Academy ,Medical Sciences ,Warm Antibody Autoimmune Hemolytic Anemia ,Prior Lines ,Subgroup Analysis ,Huazhong University ,Heavily Pre Treated Hodgkin Lymphoma ,Cancer Center ,Final Result ,Dose Expansion ,University People ,Advanced Acute Myeloid Leukemia ,Isocitrate Dehydrogenase ,Preliminary Results ,Dose Escalation ,Shanghai Jiao Tong University School ,Escalation Study ,Third Generation ,Highly Selective ,Chinese Patients ,Preliminary Efficacy ,Syk Inhibitor ,Adult Subjects ,Securities Litigation Reform Act ,Stock Exchange ,Hong Kong Limited ,Alex Shaw ,